DNA hypomethylation and human diseases.
By Ann Wilson, B. Power, P. Molloy. Biochimica et Biophysica Acta, 2007
810 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/4d289d7f1baab1bed28c01b37e3a4e4bad64f3ae
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- Peter A. Jones
- Manel Esteller
- Miho M. Suzuki
- A. Bird
- T. Miranda
- Manuel Rodríguez‐Paredes
- Jian‐Kang Zhu
- Andrew P. Feinberg
In Molecular Biology
- Peter A. Jones
- Manel Esteller
- A. Bird
- Anna Portela
- T. Miranda
- Miho M. Suzuki
- Andrew P. Feinberg
- Manuel Rodríguez‐Paredes
Citations in the corpus
- Active DNA Demethylation Mediated by DNA Glycosylases (2009, positive): “Sequences with hypomethylation in cancers include repetitive sequences, imprinted genes, tissue-specific genes, oncogenes, and genes associated with invasion and metastases (54, 104).”
- DNA methylation: The nuts and bolts of repression (2007, background): “This hypomethylation leads to the expansion of the parasitic elements, and may play a role in carcinogenesis (Wilson et al., 2007).”
- Phenotypic plasticity and the epigenetics of human disease (2007, background): “, and we now know that many growth-promoting genes are activated through hypomethylation in tumours, including HRAS , cyclin D2 and maspin in gastric cancer, carbonic anhydrase IX in renal-cell cancer, and S100 calcium-binding protein A4 in colon cancer (see ref”
- Epigenetic modifications and human disease (2010, background): “A clear case is the LINE family member L1, which has been shown to be hypomethylated in a wide range of cancers, including breast, lung, bladder and liver tumor”
- Cancer epigenetics reaches mainstream oncology (2011, background): “Furthermore, aberrant DNA hypomethylation can also account for the activation of some protooncogenes and lead to loss of imprinting, as in the case of the IGF2 gene (encoding insulin-like growth factor-2) in Wilms's tumo”
- DNA methylation landscapes: provocative insights from epigenomics (2008, background): “So far, neither DNA methyltransferase gene mutants nor naturally hypomethylated cells, such as tumour cells, have betrayed evidence of enhanced transpositio”